About the Authors
- Jaime Moreno
-
Roles Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft
Affiliation Digital Science and Innovation, Computational Biology – AI & Digital Research, Novo Nordisk A/S, Maløv, Denmark
- Lise Lotte Gluud
-
Roles Validation, Writing – review & editing
Affiliations Gastro Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark, Dept of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- Elisabeth D. Galsgaard
-
Roles Validation, Writing – review & editing
Affiliation Global Translation, Novo Nordisk A/S, Maløv, Denmark
- Henning Hvid
-
Roles Resources, Validation, Writing – review & editing
Affiliation Global Drug Discovery, Novo Nordisk A/S, Maløv, Denmark
- Gianluca Mazzoni
-
Roles Conceptualization, Funding acquisition, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: gcma@novonordisk.com (GM); vvda@novonordisk.com (VD)
Affiliation Digital Science and Innovation, Computational Biology – AI & Digital Research, Novo Nordisk A/S, Maløv, Denmark
- Vivek Das
-
Roles Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing – review & editing
* E-mail: gcma@novonordisk.com (GM); vvda@novonordisk.com (VD)
Affiliation Digital Science and Innovation, Computational Biology – AI & Digital Research, Novo Nordisk A/S, Maløv, Denmark
Competing Interests
I have read the journal’s policy and the authors of this manuscript have the following competing interests: VD, JM, GM, EDG and HH are employed by Novo Nordisk A/S. VD, JM, GM, HH and EDG hold minor stock portions as part of an employee-offering program. The authors have also indicated that no competing interests exist. Author Lise Lotte Gluud has received speaker honorarium from Norgine, Astra Zeneca, Sobi, Alexion and Novo Nordisk, consultant honorarium from Pfizer, Becton, Dickinson and Novo Nordisk and research funding from Alexion, Gilead Sciences and Novo Nordisk.